JGC
LFCR icon

J. Goldman & Co’s Lifecore Biomedical LFCR Stock Holding History

J. Goldman & Co’s Portfolio LFCR Stock Details LFCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-46,330
Closed -$427K – 398
2021
Q3 		$427K Sell
46,330
-222,120
-83% -$2.42M 0.02% 287
2021
Q2 		$3.02M Buy
+268,450
New +$3.09M 0.12% 190
2020
Q2 		– Sell
-64,262
Closed -$558K – 310
2020
Q1 		$558K Buy
+64,262
New +$669K 0.07% 163
2019
Q2 		– Sell
-46,457
Closed -$570K – 309
2019
Q1 		$570K Sell
46,457
-34,595
-43% -$422K 0.03% 228
2018
Q4 		$960K Buy
81,052
+40,476
+100% +$556K 0.07% 185
2018
Q3 		$584K Buy
+40,576
New +$561K 0.04% 217

Other funds holding LFCR

WC
Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return
LPAM
Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ICM
ISZO Capital Management New York $2M AUM 35.61% 1-Year Est. Return
CSC
Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
Heartland Advisors Milwaukee, Wisconsin $1.96B AUM 28.26% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

J. Goldman & Co's LFCR Position: Q4 2021 in Review

J. Goldman & Co sold out of Lifecore Biomedical (LFCR) in Q4 2021, closing a stake of 46,330 shares — an estimated $427K sold.

J. Goldman & Co first reported a position in LFCR in Q3 2018 and held it in 6 quarters. The position peaked at $3.02M in Q2 2021. 98 funds tracked by Wall St. Rank hold LFCR as of Q4 2021.

  • J. Goldman & Co reported no remaining Lifecore Biomedical position as of Q4 2021 after selling out during the quarter.
  • J. Goldman & Co sold 46,330 Lifecore Biomedical shares in Q4 2021, an estimated $427K.
  • J. Goldman & Co first reported a position in Lifecore Biomedical in Q3 2018 and held it in 6 quarters.
  • J. Goldman & Co's Lifecore Biomedical position peaked at $3.02M in Q2 2021.
  • 98 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q4 2021.

Based on J. Goldman & Co's 13F filing for Q4 2021, filed 14 Feb 2022.